Abstract: Non-small cell lung cancer（NSCLC） remains the leading cause of cancer-related mortality globally. In recent years,the advent of molecular targeted therapies and immune checkpoint inhibition has profoundly reshaped the therapeutic landscape of NSCLC. As these advanced modalities shift from treating advanced-stage disease toward earlier-stage presentations,perioperative intervention (including neoadjuvant and adjuvant therapy) has risen to the forefront of NSCLC research. To comprehensively address the integration of targeted and immunotherapeutic strategies in the perioperative management of NSCLC research,this review synthesizes the core findings from landmark phase Ⅲ randomized controlled trials such as NeoADAURA and CheckMate 816. Additionally,it presents a succinct summary and analysis of the principal prognostic endpoints used to evaluate perioperative efficacy. Drawing on current evidence related to both efficacy and safety,the review advocates for an individualized precision-oncology approach as a pivotal direction for optimizing perioperative treatment strategies in NSCLC research.

Key words: lung cancer;perioperative therapy;targeted therapy;immunotherapy